ArticlePloS one2014
Metabolomics as a tool for discovery of biomarkers of autism spectrum disorder in the blood plasma of children.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02548442 (Children's Autism Metabolome Project), which is not on this map. Cited by 87 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Children's Autism Metabolome Project (CAMP): Development and Clinical Evaluation of the Stemina Metabolic Biomarker-Based Test to Diagnose Autism Spectrum Disorder in Early Childhood
Who cites it
87 citing papers in PubMed, 3 syntheses or guidelines pooled it, 151 citations in OpenAlex.
- Biomarkers and pathways in autism spectrum disorder: An individual meta-analysis based on proteomic and metabolomic data.European archives of psychiatry and clinical neuroscience · 2025Pooled it
- Scoping review of precision child and youth mental health research: dwelling in possibility.Frontiers in psychiatry · 2025Pooled it
- Integrative analysis of genetic data sets reveals a shared innate immune component in autism spectrum disorder and its co-morbidities.Genome biology · 2016Pooled it
- Identification of urinary metabolites that correlate with clinical improvements in children with autism treated with sulforaphane from broccoli.Molecular autism · 2018Trial
- Gut mucosal barrier: the frontline of bidirectional regulation of the gut-X axis.Medical review (2021) · 2026Review
- Article
- Machine learning model to identify gut microbiome-derived metabolites as potential biomarkers of autism spectrum disorder: a pilot study.BMC psychiatry · 2026Article
- Autism and the gut metabolome: Evidence for altered short-chain fatty acid profiles from a systematic review and meta-analysis.Brain, behavior, & immunity - health · 2026Review
- Newborn metabolomics linking prenatal air pollution exposure and autism spectrum disorder risk in children.Journal of exposure science & environmental epidemiology · 2026Article
- Plasma metabolomic signatures in children with autism spectrum disorder and their modulation following a gluten-free modified ketogenic diet.BMC psychiatry · 2026Article
- The role of machine learning in autism spectrum disorder assessment and management.Pediatric research · 2025Review
- Beyond the gut: decoding the gut-immune-brain axis in health and disease.Cellular & molecular immunology · 2025Review
- Gut and Metabolic Biomarkers in Autism Spectrum Disorder: A Systematic Review of Body Fluid Signatures for Early Detection.Journal of autism and developmental disorders · 2025Article
- The Metabolic Signature of Autism Spectrum Disorders Using Dried Blood Spots at Birth.Psychiatry investigation · 2025Article
- Targeted metabolomics in children with autism spectrum disorder with and without developmental regression.Metabolic brain disease · 2025Article
- Amino Acid Patterns in Children with Autistic Spectrum Disorder: A Preliminary Biochemical Evaluation.Nutrients · 2025Article
- Dysregulated metabolic pathways associated with air pollution exposure and the risk of autism: Evidence from epidemiological studies.Environmental pollution (Barking, Essex : 1987) · 2024Review
- LC-HRMS Lipidomic Fingerprints in Serbian Cohort of Schizophrenia Patients.International journal of molecular sciences · 2024Article
- Unraveling the metabolomic architecture of autism in a large Danish population-based cohort.BMC medicine · 2024Article
- Review
27 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe diagnosis of autism spectrum disorder (ASD) at the earliest age possible is important for initiating optimally effective intervention. In the United States the average age of diagnosis is 4 years. Identifying metabolic biomarker signatures of ASD from blood samples offers an opportunity for development of diagnostic tests for detection of ASD at an early age.
objectivesTo discover metabolic features present in plasma samples that can discriminate children with ASD from typically developing (TD) children. The ultimate goal is to identify and develop blood-based ASD biomarkers that can be validated in larger clinical trials and deployed to guide individualized therapy and treatment.
methodsBlood plasma was obtained from children aged 4 to 6, 52 with ASD and 30 age-matched TD children. Samples were analyzed using 5 mass spectrometry-based methods designed to orthogonally measure a broad range of metabolites. Univariate, multivariate and machine learning methods were used to develop models to rank the importance of features that could distinguish ASD from TD.
resultsA set of 179 statistically significant features resulting from univariate analysis were used for multivariate modeling. Subsets of these features properly classified the ASD and TD samples in the 61-sample training set with average accuracies of 84% and 86%, and with a maximum accuracy of 81% in an independent 21-sample validation set.
conclusionsThis analysis of blood plasma metabolites resulted in the discovery of biomarkers that may be valuable in the diagnosis of young children with ASD. The results will form the basis for additional discovery and validation research for 1) determining biomarkers to develop diagnostic tests to detect ASD earlier and improve patient outcomes, 2) gaining new insight into the biochemical mechanisms of various subtypes of ASD 3) identifying biomolecular targets for new modes of therapy, and 4) providing the basis for individualized treatment recommendations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.